@article {Hiasejhpharm-2022-003305, author = {Julie Hias and Laura Hellemans and Karolien Walgraeve and Jos Tournoy and Christophe Vandenbriele and Lucas Van Aelst and Lorenz Roger Van der Linden}, title = {Should vericiguat be initiated in geriatric inpatients with heart failure with reduced ejection fraction and a worsening heart failure event prior to discharge?}, elocation-id = {ejhpharm-2022-003305}, year = {2022}, doi = {10.1136/ejhpharm-2022-003305}, publisher = {BMJ Specialist Journals}, abstract = {Heart failure (HF) occurs predominantly in older adults. HF patients have an increased risk for an acute exacerbation, which commonly requires hospitalisation. Such a worsening HF (WHF) event has an impact on prognosis. Vericiguat is a novel agent which has been shown to reduce the HF hospitalisation risk in patients with a recent WHF event. It is not fully clear how to position this novel agent in geriatric HF inpatients.}, issn = {2047-9956}, URL = {https://ejhp.bmj.com/content/early/2022/05/18/ejhpharm-2022-003305}, eprint = {https://ejhp.bmj.com/content/early/2022/05/18/ejhpharm-2022-003305.full.pdf}, journal = {European Journal of Hospital Pharmacy} }